![](images/graphics/blank.gif)
Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy
Chia sẻ: ViNaypyidaw2711 ViNaypyidaw2711 | Ngày: | Loại File: PDF | Số trang:10
![](images/blank.gif)
16
lượt xem 2
download
lượt xem 2
download
![](https://tailieu.vn/static/b2013az/templates/version1/default/images/down16x21.png)
APF530 provides controlled, sustained-release granisetron for preventing acute (0–24 h) and delayed (24–120 h) chemotherapy-induced nausea and vomiting (CINV). In a phase III trial, APF530 was noninferior to palonosetron in preventing acute CINV following single-dose moderately (MEC) or highly emetogenic chemotherapy (HEC) and delayed CINV in MEC (MEC and HEC defined by Hesketh criteria).
Chủ đề:
Bình luận(0) Đăng nhập để gửi bình luận!
![](images/graphics/blank.gif)
CÓ THỂ BẠN MUỐN DOWNLOAD